

The Quantitative Imaging Biomarkers Alliance (*QIBA*) was organized by RSNA in 2007 to unite researchers, healthcare professionals, and industry stakeholders in the advancement of quantitative imaging and the use of biomarkers in clinical trials and practice.

Quantitative imaging is the acquisition, extraction and characterization of relevant quantifiable features from medical images for use in research and patient care. Standardizing the use of imaging biomarkers in clinical trials will reduce the variance inherent across different hardware and software platforms. RSNA views this work as a step toward an ultimate goal of enhancing the use of quantitative imaging methods in clinical practice.

QIBA is an important part of RSNA's commitment to transforming radiology from a *qualitative* to a more *quantitative* science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.

### **QIBA Mission**

***Improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, patients and time.***

The work of QIBA has advanced through the generous efforts of volunteer members from academia, the medical device industry, the pharmaceutical and other business sectors, and government. There are 12 biomarker committees open to all interested persons. These Committees have specific tasks and deliverables for their respective modalities and disease-based approach:

**Arterial Spin Labeling (ASL) [EIBIR]**

**CT Volumetry**

**Lung Density**

**fMRI**

**MRE**

**Perfusion, Diffusion and Flow MRI (PDF-MRI)**

**Proton Density Fat Fraction (PDFF)**

**FDG-PET/CT**

**PET-Amyloid**

**SPECT**

**Ultrasound Shear Wave Speed (US-SWS)**

**Ultrasound Volume Blood Flow (US-VBF) [AIUM]**

**Contrast Enhanced Ultrasound (CEUS)**

### **The QIBA Approach**

The work of the QIBA Committees follows a defined, coordinated process to develop solutions and promote their adoption.

**I. Identify Sources of Error and Variation in Quantitative Results from Imaging Methods:** Stakeholders work to identify problems leading to error or variability in quantitative results from imaging methods.

**II. Specify Potential Solutions:** Stakeholders identify potential strategies and infrastructure for error mitigation and collaborate on development of hardware, software, and protocol solutions, documenting them in the form of QIBA Profiles.

**III. Test Solutions:** Vendors and researchers implement QIBA solutions to assess their feasibility and efficacy.

**IV. Promulgate Solutions:** Validated solutions are disseminated and implemented through vendor adoption, research integration and clinical education.

### **QIBA Resources**

QIBA meeting summaries, key criteria for identifying biomarker opportunities, the *QIBA Newsletter* and other documents are available on the QIBA website [RSNA.ORG/QIBA](http://RSNA.ORG/QIBA) and wiki <http://qibawiki.rsna.org/>

**Volunteers for the QIBA Committees are welcome; please contact us at: [qiba@rsna.org](mailto:qiba@rsna.org)**

# QIBA Committees

## QIBA Governance Structure

<b>QIBA Chair:</b>	Edward F. Jackson, PhD	(University of Wisconsin, School of Medicine & Public Health)
<b>QIBA Vice Chair:</b>	Alex Guimaraes, MD, PhD	(Oregon Health & Science University)
<b>Scientific Liaison: CT:</b>	Andrew J. Buckler, MS	(Elucid Bioimaging, Inc.)
<b>Scientific Liaison: MR:</b>	Thomas L. Chenevert, PhD	(University of Michigan Health System)
<b>Scientific Liaison: NM:</b>	Paul E. Kinahan, PhD	(University of Washington)
<b>Scientific Liaison: US:</b>	Paul L. Carson, PhD	(University of Michigan Health System)

---

## Process Committee

### Process Committee

<b>Chair:</b>	Kevin O'Donnell, MASC	(Toshiba Medical Research Institute USA, Inc.)
<b>Vice Chair:</b>	Daniel Sullivan, MD	(Duke University Medical Center)

---

## Coordinating Committees

### Computed Tomography (CT) Coordinating Committee

<b>Co-Chairs:</b>	Rudresh Jarecha, MBBS, DNB, DMRE	(PARAXEL International)
	Lawrence Schwartz, MD	(New York Presbyterian Hospital / Columbia University)
<b>Vice Chair:</b>	David Lynch, MD	(National Jewish Health)

### Nuclear Medicine (NM) Coordinating Committee

<b>Co-Chairs:</b>	Richard Wahl, MD	(Mallinckrodt Institute, Washington University)
	Eric Perlman, MD	(Perlman Advisory Group, LLC)
<b>Vice Chair:</b>	P. David Mozley, MD	(Endocyte, Inc.)

### Magnetic Resonance Imaging (MR) Coordinating Committee

<b>Co-Chairs:</b>	Mark Rosen, MD, PhD	(University of Pennsylvania)
	Gudrun Zahlmann, PhD	(Roche Pharmaceuticals)
<b>Vice Chair:</b>	Cathy Elsinger, PhD	(NordicNeuroLab, Inc.)

### Ultrasound (US) Coordinating Committee

<b>Chair:</b>	Tim Hall, PhD	(University of Wisconsin, School of Medicine & Public Health)
<b>Vice Chair:</b>	Brian Garra, MD	(Washington DC VA Medical Center / FDA)

---

## **Biomarker Committees (by imaging modality)**

### **CT Volumetry**

#### **Co-Chairs:**

Gregory V. Goldmacher, MD, PhD, MBA (Merck)  
Ehsan Samei, PhD (Duke University Medical Center)  
Jenifer Siegelman, MD, MPH (Harvard Medical School / Brigham and Women's Hospital)

### **Lung Density**

#### **Chair:**

Sean Fain, PhD (University of Wisconsin, School of Medicine & Public Health)  
Matthew Fuld, PhD (Siemens Medical Solutions USA, Inc.)  
David Lynch, MD (National Jewish Health)

---

### **Arterial Spin Labeling (ASL) [Supported by EIBIR]**

Eric Achten, PhD (University Hospital of Ghent)  
Xavier Golay, PhD (University College London)  
Matthias Guenther, PhD (Fraunhofer MEVIS)

### **Proton Density Fat Fraction**

#### **Co-Chairs:**

Scott Reeder, MD, PhD (University of Wisconsin, School of Medicine & Public Health)  
Claude Sirlin, MD (University of California, San Diego)

### **Perfusion, Diffusion and Flow - MRI**

#### **Co-Chairs:**

Michael Boss, PhD (NIST)  
John Kirsch, PhD (Siemens Medical Solutions USA, Inc.)  
Daniel Barboriak, MD (Duke University)

### **fMRI**

#### **Co-Chairs:**

Edgar DeYoe, PhD (Medical College of Wisconsin)  
Jeffrey Petrella, MD (Duke University Medical Center)  
James Reuss, PhD (Prism Clinical Imaging, Inc.)

### **MRE**

#### **Co-Chairs:**

Patricia Cole, PhD, MD (Takeda Pharmaceuticals)  
Richard Ehman, MD (Mayo Clinic)

---

### **FDG-PET**

#### **Co-Chairs:**

Rathan Subramaniam, MD, PhD, MPH (University of Texas, Southwestern Medical Center)  
John J. Sunderland, PhD (University of Iowa)  
Scott Wollenweber, PhD (GE Healthcare)

### **PET-Amyloid**

#### **Co-chairs:**

Satoshi Minoshima, MD, PhD (University of Utah)  
Eric Perlman, MD (Perlman Advisory Group, LLC)  
Anne Smith, PhD (Siemens Medical Solutions USA, Inc.)

## **SPECT**

### **Co-Chairs:**

Yuni Dewaraja, PhD	(University of Michigan Health System)
P. David Mozley, MD	(Endocyte, Inc.)
John Seibyl, MD	(Yale University / Institute for Neurodegenerative Disorders)

---

## **Ultrasound Shear Wave Speed**

### **Co-Chairs:**

Brian Garra, MD	(Washington DC VA Medical Center / FDA)
Timothy J. Hall, PhD	(University of Wisconsin, School of Medicine & Public Health)
Andy Milkowski, MS	(Siemens Medical Solutions USA, Inc.)

## **Ultrasound Volume Blood Flow [Supported by AIUM]**

### **Co-Chairs:**

J. Brian Fowlkes, PhD	(University of Michigan Health System)
Oliver Kripfgans, PhD	(University of Michigan Health System)

## **Contrast Enhanced Ultrasound (CEUS)**

### **Co-Chairs:**

Michalakis (Mike) A. Averkiou, PhD	(University of Washington, Seattle)
Richard G. Barr, MD, PhD	(Northeastern Ohio Medical University)

---